Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical comparability study of two oral semaglutide formulations in Japanese adults with type 2 diabetes
jRCT2031250491Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline to end of treatment in HbA1c. Started Dec 2025; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031250491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250491.